Workshops at BioTrinity 2008
Participation at workshops is included in the conference registration fee. However as spaces are limited, delegates are advised to register online in advance via the online partnering system's “Agenda Planner” which will soon be available to all registrants, to reserve their seats. Workshops will be held over both days of the conference, April 15-16th, 2008.
Workshop Hosts are within their right to exclude their competition from these workshop sessions, although we do not encourage this.
The following workshops will be delivered by industry experts, sharing their experiences with self-select audience, in two parallel tracks.
| Tuesday 15th April 2008 - Workshops | |
| 09:30-10:30 | Please contact OBN to reserve this workshop slot +44 (0)1865 594642 |
| 11:00-12:00 | Exploring sources of business
intelligence for biotech deal-making Workshop Details - Host: Rob Swan, Thomson Scientific |
| 11:00-12:00 | Navigating The Funding
Landscape Workshop Details - Host:Cheryl Scott, BFAS |
| 13.00-14.00 | Preparing for Investment Workshop Details Host: Patrick Baddeley, Catherine Rohll, William Downing, Manches LLP |
| 13.00-14.00 | Physical form, polymorphism and salt selection: a regulatory need, an IP and drug delivery opportunity Workshop Details Host: Graham Buckton, Pharmaterials Ltd |
| 14:15-15:15 | When 'It Hits the Fan', can I be held
personally responsible? Workshop Details - Host: Andrew Tamworth, Giles Insurance Brokers Ltd |
| 14:15-15:15 | Do's and Don't of Licensing to Big
Pharma Workshop Detail - Host: Tim Sparey, Merck Sharp & Dohme |
| Wednesday 16th April 2008 - Workshops | |
| 09:30-10:30 | Bioscience Patents: When to file and
options in the first year Workshop Detail - Host: Philip Webber, Frank B Dehn |
| 09:30-10:30 | Please contact OBN to reserve this workshop slot +44 (0)1865 594642 |
| 11:00-12:00 | Valuable Tax Breaks for Bioscience
Companies and their Investors Workshop Detail - Host: Sam Vanags and Mike Shearan, Grant Thornton UK |
| 11:00-12:00 | Achieving the optimal oral
formulation in clinical development Workshop Detail - Host: Dr Andrew Rankin, Pharmaceutical Profiles |
| 13:00-14:00 | How Biotechs Can Maximise R & D
Tax Credit Claims Workshop Detail - Host: Simon McKeown, RDP |
| 13:00-14:00 | Accessing Global Market
Opportunities: Emerging Markets Workshop Detail - Host: David Parry, SEHTA |
| 14:15-15:15 | New Gateway to European Innovation Technology and Funding Workshop Detail - Host: Richard Hall, Stimutran SME |
| 14:15-16:15 | Capture, Organise, Analyse and Share
Chemical and Biological Data to Collaborate More Effectively Workshop Detail - Host: Dr. Rob Scoffin, Cambridgesoft |
Workshop details
You can book into workshops using the online partnering system, accessible once you register. This will help us to allocate your partnering meetings around the workshops you wish to attend, helping you access everything you wish to access.
Capture, organize, analyse and share Chemical and Biological data more effectively
Dr. Rob Scoffin, VP European Operations, CambridgeSoftThis main objective of this workshop is to provide a general overview of the ChemBioOffice Ultra Desktop suite. CambridgeSoft solutions allow scientists to efficiently keep track of their work, gain a deeper understanding of their data, correlate biological activity with chemical structures, and to produce scientific reports more professionally and efficiently than ever before. In this workshop in addition to the desktop tools, we will also demonstrate, using real scientists’ workflows, CambridgeSoft’s Electronic Lab Notebook, Chemical Registration, Inventory management and Biological data analysis systems. We will also show the latest innovations on drawing tools including the new biology sketching functionalities in ChemBioDraw
When it ‘Hits the Fan’, can I be held personally responsible?
Andrew Tamworth, Business Development Director, Giles Insurance Brokers Ltd
Part 1: Patrick Baddeley Corporate Finance Partner, Manches LLP
Topics to be covered will include:
- An overview of the personal responsibility of company directors and officers
- Corporate Manslaughter
- An overview of the changes imposed by the Companies Act
- Shareholder Derivative Actions: the latest US import?
Part 2: Andrew Tamworth
The session will explain the fundamentals of Directors & Officers Liability insurance, including:
- Who will a policy protect?
- In what scenarios will a policy provide protection?
- Typical policy exclusions
- Key issues in getting the cover right
- Protection for key events and fundraising, IPO, M&A, etc
Valuable Tax Breaks for BioScience Companies and their Investors
Sam Vanags and Mike Shearan, Grant Thornton LLP UK
The UK tax system can reduce the net proceeds due to bioscience companies and their investors, but there are a number of important tax relief’s which can radically improve the situation.
Sam Vanags and Mike Shearan from Grant Thornton provide an "insider's guide" to these constantly evolving tax breaks, including:
- Optimising R&D tax credits;
- Tax relief’s for investors (EIS and VCTs), including complete CGT exemption;
- The new "Entrepreneurs' Relief"
- Share schemes' added value for companies
Dos and Don'ts of Licensing to Big Pharma
Tim Sparey, PhD, Merck Sharp & DohmeLicensing to big Pharma has increased dramatically in recent years. Competition to attract big Pharma has also increased. This presentation will inform of what companies are looking for in a licensing partner and also give an overview of what Merck Sharp & Dohme is looking to license in.
Achieving optimal oral drug delivery in clinical development
Andrew Rankin, Pharmaceutical ProfilesPoor oral absorption? Formulation issues? Need a modified release formulation? Addressing these issues in early development is commonly a matter of trial and error if you are relying on in vitro and preclinical animal data to guide your formulation development. We discuss common bioavailability issues and the approaches that we can use in clinical studies to address them in the most efficient way possible.
Accessing Global Market Opportunities: Emerging Markets
South East Health Technologies AllianceThe emerging healthcare markets of India and United Arab Emirates (UAE) are growing at a phenomenal rate. The UK is now India’s 4th largest trading partner, and needs to maintain its competitive position in this ever-changing market. Coupled with extensive infrastructure expansion, the UAE will be screening the entire population for early diagnosis of health-related illnesses. Come and find out more about accessing these opportunities from experts in the field at this SEHTA event!
Exploring sources of business intelligence for biotech deal-making
Thomson ScientificVision and luck aren’t enough to guarantee a healthy business. Successful companies grow because they've given themselves an advantage — the market knowledge and strategic intelligence on which to make fast, clever decisions. In-depth competitive intelligence, drawn from 12 million basic inventions and 23 million patents and with detailed pipeline, financial and marketing profiles of more than 7,500 companies is Thomson Scientific. Join us to discover how, when and why in our BioTrinity 2008 workshop.
Bioscience Patents: When to file and Options in the first year
Dr. Philip Webber, Frank B. Dehn & Co.The workshop will consider issues such as what can be patented in the bioscience field, what determines when to file your patent application, how broad to claim your invention and what options are available to you in the priority year.
The workshop will be presented by Dr. Philip Webber, a partner in the Life Sciences Group of Frank B. Dehn & Co. Dr. Webber is a member of the Biotechnology Committee of the Chartered Institute of Patent Attorneys (CIPA). He is a frequent speaker at conferences on the patenting of biotech inventions, as well as publishing a number of papers in this area.
Navigating The Funding Landscape
Cheryl Scott, BFASIdentifying appropriate sources of funding to help grow your business is not easy. Especially if you are a Bio-or Health Technology business. You may have longer timescales to product launch, regulatory hurdles to overcome and a requirement for larger amounts of finance at an earlier stage of company development. This workshop provides an overview of the different types of funding (grants/debt/equity) available to Bio- and health technology companies within the South East region, and then goes on to explain their positioning/relevance within the financial design and funding strategy for a growing business in this sector.
New Gateway to European Innovation Technology and Funding
Richard Hall, StimutranAn exciting new EU initiative has been launched to provide companies in the South-East with expanded access to European markets, technology and funding opportunities. The Enterprise Europe Network in the South East offers the companies in the SE: • One-to-one assistance on breaking into new European markets • Access to the latest technological innovations from across Europe • Access to the latest information on funding opportunities available through the EU’s key source of research grants: Framework Programme 7 (FP7) • Find out about public procurement opportunities and how to bid for them The Enterprise Europe Network is a significant six year initiative funded through the European Competitiveness and Innovation Programme to help SMEs across Europe develop their full potential and innovative capacity. Enterprise Europe South East brings together the services of Business Support Kent, London Technology Network and the European Information Service Centre Ltd and is funded by the European Union, supported by South East England Development Agency (SEEDA) and Business Link South East. Come and hear how your business could benefit from the many FREE services offered.
Is your Company Getting the Maximum from R&D tax credits?
Simon McKeown, RDP AssociatesTopics to be covered include:
• What are the benefits of making an R&D claim?
• Identifying eligible R&D projects & qualifying expenditures?
• How to maximise your claim
• Examples of successful claims
• Filing process and dealing with HMRC
• Common errors
• Where can you get help?
Who should attend?
The seminar is aimed at the Finance Director and CEO of any company that has a defined R&D spend or is making an investment in expanding the knowledge base of the company
Founders and Investors in SME’s may also find the seminar useful for incorporating R&D Tax Credits into the financing strategy of a company. Any £1 returned is a £1 you do not have to raise from other sources.
RDP, has been assisting a wide variety of companies obtain government
assistance for over 25 years. RDP has been practicing exclusively in this area since 1987 and Brian Cookson RDP president has lectured and written extensively on a wide variety of subjects pertaining to R&D tax credits and relief, and has presented seminars to industry groups and tax conferences. RDP employs Chartered Accountants as well as Senior Technical Associates in their high-tech services group and currently process over 200 claims per year.
Many legislative mechanisms exist, offering financial help to companies. However, the understanding and compiling of R&D tax claim may be labour intensive and may take several months.
Preparing for Investment
Patrick Baddeley/ Catherine Rohll/ William Downing, Manches LLPThis workshop will consider the situation of an early stage biotechnology company which has received an offer of investment (or partnering deal) from a pharmaceutical company subject to due diligence. We will take participants through a fictional case study that will identify a number of problem areas that are commonly encountered during due diligence and suggest strategies for dealing with them. Areas covered will include: share structures, employment problems, IP and commercial issues.
Physical form, polymorphism and salt selection: a regulatory need, an IP and drug delivery opportunity
Graham Buckton, Pharmaterials LtdIn order to get an active pharmaceutical ingredient into clinical trials it is necessary to carry out preformulation and formulation studies.
This workshop aims to address the following:
• What physico-chemical information is needed in order to develop an API into a drug product?
• Polymorphism and salts – why are these important and what opportunities do they present?
• How and when to test for polymorphs and how to understand amorphous forms
• What data are vital to generate for a company looking to license a compound to big pharma
• What will the regulator (FDA/EMEA) want to see?
Sponsor and deliver a workshop. Contact details
PROJECT PARTNERS
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
